Trials / Completed
CompletedNCT03777059
12-Week Placebo-controlled Study of Atogepant for the Preventive Treatment of Migraine in Participants With Episodic Migraine
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine (ADVANCE)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 910 (actual)
- Sponsor
- Allergan · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the safety and tolerability of atogepant 30 mg and 60 mg once a day for the prevention of migraine in participants with episodic migraine.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Atogepant | Atogepant tablet |
| DRUG | Placebo | Placebo-matching atogepant tablets |
Timeline
- Start date
- 2018-12-14
- Primary completion
- 2020-06-19
- Completion
- 2020-06-19
- First posted
- 2018-12-17
- Last updated
- 2021-07-09
- Results posted
- 2021-07-09
Locations
138 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03777059. Inclusion in this directory is not an endorsement.